# A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

> **NCT05987371** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 75 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** TQC3721 suspension for inhalation
- **DRUG:** TQC3721 matching placebo for inhalation
- **DRUG:** Salbutamol sulfate inhalation aerosol

## Key facts

- **NCT ID:** NCT05987371
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-23
- **Primary completion:** 2024-01-16
- **Final completion:** 2024-04-23
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987371, "A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05987371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*